Easily assign HRD score
The inability to repair DNA damage is referred to as homologous recombination deficiency (HRD)1. Assessing genomic alterations in the biomarkers associated with HRD is of vital importance in cancer research. However, the detection and interpretation of DNA variants can be a daunting task. Long turnaround times, complex workflows, limited samples and bioinformatic challenges often result in high costs and impede actionable data. To help overcome these challenges, QIAGEN's high-performance streamlined sequencing and bioinformatics pipeline allows you to assign an HRD score quickly and easily.The hallmark of cancer
Mutations in the homologous recombination repair pathway genes cause loss of function or deleterious effects that contribute to HRD1. HRD is an accumulation of genomic alterations and fosters genomic instability, which is the hallmark of cancer cells2,3.
Confidently asses HRD status
To determine the underlying cause of HRD, you can assess the presence of specific mutations within the key HRR genes using our QIAseq HRD Panel. Our panel and HRD classifier will help you analyze the effects of HRD. Our solutions will score your sample's HRD status by detecting genome-wide SNPs, including loss of heterozygosity (LOH), large-scale transitions (LSTs) and telomeric allelic imbalance (TAI). Knowing the HRD status will help identify tumors with defects in the HRR pathway.
Key benefits of the QIAseq HRD Panel
-
Sensitive
- Digital sequencing enabled by unique molecular indices to remove PCR duplicates
- Complete Sample to Insight solution streamlines the workflow
-
Robust
- Compatibility with low-quality DNA enables efficient sequencing of FFPE and cfDNA samples
- Minimal DNA input to preserve precious samples
- Optimized buffers and conditions to achieve high coverage of GC-rich regions
-
Flexible
- Custom panel to fit your every NGS need
- Compatible with all major NGS platforms
A simple solution to your complex problem
The complete Sample to Insight workflow begins with DNA extraction, followed by library construction and target enrichment with QIAseq HRD Panels. Following NGS, data analysis is performed using the QIAGEN CLC Genomics Workbench. Detected variants can be interpreted with QIAGEN Clinical Insight (QCI) for QIAseq. Our QIAseq HRD Panel and classifier will allow you to determine the HRD status of your sample by assessing all the genomic alterations including LSTs, LOH and TAI.
References
- Min, A. et.al. (2020) Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. Nat. Sci. Rep. 10, 12506
-
Hoppe, M.M., Sundar, R., Tan, D., Jeyasekharan, A.D. (2018) J. Natl. Cancer Inst. 110(7), 704–713
-
Konstantinopoulos, P.A., Ceccaldi, R., Shapiro, G.I. and Andrea, A.D. (2015) Cancer Discov. 5(11), 1137–1154
The products mentioned here are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.